Isoprinosine in the treatment of children with frequent
respiratory tract infections and minor T-lymphocyte
immunodeficiency

J 1999

Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency

LITZMAN, Jiří, Marcela KREJČÍ, Sáva PEŠÁK and Jindřich LOKAJ

Basic information

Original name

Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency

Authors

LITZMAN, Jiří (203 Czech Republic, guarantor), Marcela KREJČÍ, Sáva PEŠÁK (203 Czech Republic) and Jindřich LOKAJ (203 Czech Republic)

Edition

Scripta Medica (Brno), Brno, LF MU Brno, 1999, 1211-3395

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30209 Paediatrics

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/99:00003614

Organization unit

Faculty of Medicine

Keywords in English

inosine pranobex; immunodeficiency; immunotherapy

Abstract

V originále

Isoprinosine is a T-lymphocyte enhancing agent sometimes recommended for the treatment of patients with T-lymphocyte deficiency and clinical signs of immunodeficiency. We performed a double-blind trial of treatment of children aged 4-8 years with frequent respiratory tract infection and laboratory signs of T-lymphocyte deficiency - decreased absolute or relative numbers of E-rosette forming cells, CD3+ and CD4+ lymphocytes or increased numbers of CD8+ cells. Thirty two children that finished the study were given isoprinosine and 25 placebo. We could not show any clinical benefit of the administration of isoprinosine on the frequency or severity of respiratory tract infections compared to placebo. An increase in the number of E-rosette forming cells, CD4+ and CD3+ lymphocytes was observed after 6 weeks of isoprinosine administration, but similar, although not significant, changes were observed in the placebo treated group.

Links

NI4703, research and development project

Name: Poruchy imunoregulace u nemocných s humorálními imunodeficity

Investor: Ministry of Health of the CR, Immunoregulatory defects in patients with humoral immunodeficiencies

Citovat

LITZMAN, Jiří, Marcela KREJČÍ, Sáva PEŠÁK and Jindřich LOKAJ. Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency. Scripta Medica (Brno). Brno: LF MU Brno, 1999, vol. 72, No 4, p. 115-124. ISSN 1211-3395.

@article{226532,
   author = {Litzman, Jiří and Krejčí, Marcela and Pešák, Sáva and Lokaj, Jindřich},
   article_location = {Brno},
   article_number = {4},
   keywords = {inosine pranobex; immunodeficiency; immunotherapy},
   language = {eng},
   issn = {1211-3395},
   journal = {Scripta Medica (Brno)},
   title = {Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency},
   volume = {72},
   year = {1999}
}

TY  - JOUR
ID  - 226532
AU  - Litzman, Jiří - Krejčí, Marcela - Pešák, Sáva - Lokaj, Jindřich
PY  - 1999
TI  - Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency
JF  - Scripta Medica (Brno)
VL  - 72
IS  - 4
SP  - 115
EP  - 115
PB  - LF MU Brno
SN  - 12113395
KW  - inosine pranobex
KW  - immunodeficiency
KW  - immunotherapy
N2  - Isoprinosine is a T-lymphocyte enhancing agent sometimes recommended for the treatment of patients with T-lymphocyte deficiency and clinical signs of immunodeficiency. We performed a double-blind trial of treatment of children aged 4-8 years with frequent respiratory tract infection and laboratory signs of T-lymphocyte deficiency - decreased absolute or relative numbers of E-rosette forming cells, CD3+ and CD4+ lymphocytes or increased numbers of CD8+ cells. Thirty two children that finished the study were given isoprinosine and 25 placebo. We could not show any clinical benefit of the administration of isoprinosine on the frequency or severity of respiratory tract infections compared to placebo. An increase in the number of E-rosette forming cells, CD4+ and CD3+ lymphocytes was observed after 6 weeks of isoprinosine administration, but similar, although not significant, changes were observed in the placebo treated group.
ER  -

LITZMAN, Jiří, Marcela KREJČÍ, Sáva PEŠÁK and Jindřich LOKAJ. Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency. \textit{Scripta Medica (Brno)}. Brno: LF MU Brno, 1999, vol.~72, No~4, p.~115-124. ISSN~1211-3395.

Detailed Information on Publication Record